# Treatment of Adult ADHD With Atomoxetine or Atomoxetine and Buspar

> **NCT00174226** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 241 (actual)

## Conditions studied

- Attention Deficit Disorder With Hyperactivity

## Interventions

- **DRUG:** Atomoxetine
- **DRUG:** Buspirone

## Key facts

- **NCT ID:** NCT00174226
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-11
- **Primary completion:** —
- **Final completion:** 2006-01
- **Target enrollment:** 241 (ACTUAL)
- **Last updated:** 2008-07-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00174226

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00174226, "Treatment of Adult ADHD With Atomoxetine or Atomoxetine and Buspar". Retrieved via AI Analytics 2026-08-17 from https://api.ai-analytics.org/clinical/NCT00174226. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*